PALI is the ticker symbol for PALISADE BIO, INC., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks PALI with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is PALI a good stock to buy?

PALI is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/PALI.

Where does 13F Pro source PALI data?

All PALISADE BIO, INC. fundamentals and ownership data come directly from SEC EDGAR. PALISADE BIO, INC. files with the SEC under CIK 1357459. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

PALISADE BIO, INC.(PALI)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

PALISADE BIO, INC. (PALI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. PALI is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.7m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), PALISADE BIO, INC. reports quarterly revenue of $500.0K, net income of $-10.6M. Top institutional holders of PALI by reported 13-F value include Soleus Capital Management, L.P., B Group, AMERIPRISE FINANCIAL, based on the most recent SEC filings. PALI trades on the Nasdaq exchange and files with the SEC under CIK 1357459. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PALI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PALISADE BIO, INC. directly from SEC EDGAR.

Revenue

$500.0K

Net Income

$-10.6M

PALI key financials by period

PALISADE BIO, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2023	10-K	$250.0K	$-12.3M	—
FY 2020	10-K	$13.5K	$-10.3M	—
FY 2019	10-K	$15.4K	$-8.4M	—
FY 2018	10-K	$260.0K	$-4.9M	—
FY 2017	10-K	$260.0K	$-15.7M	—
FY 2016	10-K	$16.2K	$-21.1M	—

Institutions holding PALI

Institutional investors reporting a position in PALISADE BIO, INC. on SEC Form 13F.
Institution	Shares	Value	Reported
Soleus Capital Management, L.P.	13,063,687	$27.3M	2026-06-30
B Group	11,414,285	$23.9M	2026-06-30
AMERIPRISE FINANCIAL	11,081,434	$23.2M	2026-06-30
Jupiter Topco	10,689,452	$22.4M	2026-06-30
BlackRock	10,436,760	$21.8M	2026-06-30
Octagon Capital Advisors	10,276,317	$21.5M	2026-06-30
PERCEPTIVE ADVISORS	8,425,065	$17.6M	2026-06-30
RA CAPITAL MANAGEMENT, L.P.	7,124,116	$14.9M	2026-06-30
FRANKLIN RESOURCES	5,785,189	$12.1M	2026-06-30
Point72 Asset Management, L.P.	5,253,403	$11.0M	2026-06-30

SEC EDGAR: CIK 1357459 →

PALISADE BIO, INC.

PALI

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.7M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.